

MANAGEMENT'S RESPONSIBILITY FOR FINANCIAL REPORTING

The accompanying unaudited condensed interim consolidated financial statements of Nutritional High International Inc., are the responsibility of the management and Board of Directors of the Company.

The unaudited condensed interim consolidated financial statements have been prepared by management, on behalf of the Board of Directors, in accordance with the accounting policies disclosed in the notes to the consolidated financial statements. Where necessary, management has made informed judgments and estimates in accounting for transactions which were not complete at the consolidated statement of financial position date. In the opinion of management, the consolidated financial statements have been prepared within acceptable limits of materiality and are in accordance with International Financial Reporting Standards using accounting policies consistent with International Financial Reporting Standards appropriate in the circumstances.

Management has established systems of internal control over the financial reporting process, which are designed to provide reasonable assurance that relevant and reliable financial information is produced.

The Board of Directors is responsible for reviewing and approving the unaudited condensed interim consolidated financial statements together with other financial information of the Company and for ensuring that management fulfills its financial reporting responsibilities. An Audit Committee assists the Board of Directors in fulfilling this responsibility. The Audit Committee meets with management to review the financial reporting process and the unaudited condensed interim consolidated financial statements together with other financial information of the Company. The Audit Committee reports its findings to the Board of Directors for its consideration in approving the unaudited condensed interim consolidated financial statements together with other financial information of the Company for issuance to the shareholders.

Management recognizes its responsibility for conducting the Company's affairs in compliance with established financial standards, and applicable laws and regulations, and for maintaining proper standards of conduct for its activities.

<u> "David Posner" </u>	_, Director and CEO	<u>"Al Quong"</u>	_, CFO
David Posner	-	Al Quong	_

Nutritional High International Inc. Unaudited Condensed Interim Consolidated Statements of Financial Position

(Expressed in Canadian Dollars)

	October 31, 2015	July 31, 2015
Assets	(unaudited)	(audited)
Current		
Cash	\$ 103,135	\$ 19,567
HST receivable (Note 4)	45,626	121,572
Other receivable	-	9,459
Prepaids (Note 17)	146,788	238,115
	295,549	388,713
Non-current assets		
Amounts due from Palo Verde LLC (Note 5 and 20)	287,119	197,842
Prepaid license (Note 17 and 20)	245,617	249,780
Investment property (Note 6)	1,119,132	1,129,582
Property deposits (Note 7)	13,206	6,671
	\$ 1,960,623	\$1,972,588
Liabilities		
Current		
Accounts payable and accrued liabilities (Notes 8 and 9)	\$ 370,138	\$ 272,274
Non-current liabilities		
Convertible debentures (Note 14 and 20)	374,182	539,910
Derivative liability (Note 14 and 20)	296,279	330,065
	1,040,599	1,142,249
Shareholders' Equity		
Share Capital (Note 10 and 20)	3,101,920	2,719,740
Shares to be issued	50,000	-
Reserve for share based payments (Note 11 and 20)	333,000	314,000
Reserve for warrants (Note 10 and 12)	566,360	566,399
Reserve for foreign currency translation	(15,339)	(15,285)
Non-controlling interest (Note 13)	(8,920)	(9,073)
Loss on acquisition of non-controlling interest (Note 13)	(5,000)	(5,000)
Accumulated deficit (Note 20)	(3,101,997)	(2,740,442)
	920,024	830,339
	\$ 1,960,623	\$1,972,588

Nature of Operations and Going concern (Note 1)

Licensing and Royalty Agreement (Note 17)

Subsequent Events (Note 19)

Approved on behalf of the Board:

"Adam Szweras"

Director

"David Posner"

Director

Nutritional High International Inc. Unaudited Condensed Interim Consolidated Statements of Loss and Comprehensive Loss

(Expressed in Canadian Dollars)

For the three months ended October 31		2015		2014
		(unaudited)		(unaudited)
Administrative expenses				
Management and consulting fees (Note 9)	\$	196,666	\$	158,950
Professional fees (Note 9)		24,717		178,073
Office and general		72,052		47,799
Share based payments (Note 11 and 20)		19,000		4,000
Other Expenses				
Change in fair value of derivative liability (Note 14 and 20)		93,190		-
Finance costs (Note 14 and 20)		32,420		-
Amortization (Note 6 and 20)		14,247		-
Total expenses		(452,292)		(383,822)
Other income (Expense)				
Interest (Note 20)		10,203		1,095
Rental income (Note 5)		125,687		-
Allowance for amounts receivable (Note 5 and 20)		(45,000)		-
Net loss		(361,402)		(382,727)
Other Comprehensive loss				
Item that may be reclassified subsequently to net income/loss				
Exchange differences on translating foreign operations		54		(2,279)
Net loss and comprehensive loss	\$	(361,348)	\$	(385,006)
Net income (loss) attributable to non-controlling interest (Note 13)	\$	153	\$	(1,059)
Net loss attributable to parent company		(361,555)		(381,668)
	\$	(361,402)	\$	(382,727)
Net income (loss) and comprehensive loss attributable to non-				
controlling interest (Note 13)	\$	153	\$	(1,066)
Net loss and comprehensive loss attributable to parent				
company		(361,501)		(383,940)
	\$	(361,348)	\$	(385,006)
Weighted average number of shares outstanding				
- Basic and diluted		120,410,852		72,995,877
Loss per share		120,710,032		12,333,011
- Basic and diluted	\$	(0.003)	\$	(0.005)
Dusic and under	Ψ	(0.000)	Ψ	(0.000)

Nutritional High International Inc. Unaudited Condensed Interim Consolidated Statements of Changes in Shareholders' Equity

(Expressed in Canadian Dollars)

	Share Capital										
	Number of shares	Amount	Loss on acquisition of non-controlling interest	Reserve for Share based payments	Reserve for Warrants	Reserve for Foreign Exchange	Shares to be issued	Accumulated Deficit	Attributable to owners of Parent	Non-controlling interest	Total
Balance at July 31, 2014	71,913,631 \$	1,063,482 \$	- \$	28,000 \$	65,000 \$	- \$	- \$	(681,155) \$	475,327 \$	- \$	475,327
Private placements (Note 10)	4,000,000	100,000	-	-	-	-	-	-	100,000	-	100,000
Finders warrants issued in connection with private placements (Note 10)	-	(24,000)	-	-	24,000	-	-	-	-	-	-
Shares issued on exercise of warrants	3,566,638	195,799	-	-	(17,467)	-	-	-	178,332	-	178,332
Share based payments	-	-	-	4,000	-	-	-	-	4,000	-	4,000
Share issue costs	-	(10,219)	-	-	-	-	-	-	(10,219)	-	(10,219)
Exchange gain on translating foreign operations	-	-	-	-	-	(2,272)	-	-	(2,272)	-	(2,272)
Net loss and comprehensive loss for the period	-	-	-	-	-	-	-	(381,668)	(381,668)	(1,066)	(382,734)
Balance at October 31, 2014	79,480,269 \$	1,325,062 \$	- \$	32,000 \$	71,533 \$	(2,272) \$	- \$	(1,062,823) \$	363,500 \$	(1,066) \$	362,434
Initial public offering (Note 10)	32,900,000	1,282,000	-	-	363,000	-	-	-	1,645,000	-	1,645,000
Compensation warrants issued in connection with initial public offering (Note 10)	-	(63,000)	-	-	63,000	-	-	-	-	-	-
Warrants issued in connection to early and regular exercise of warrants (Note 12)	-	(71,000)	-	-	71,000	-	-	-	-	-	-
Shares issued on exercise of warrants (Note 10)	1,478,000	133,153	-	-	(37,134)	-	-	-	96,019	-	96,019
Issued for non-cash consideration:											
Issued for success fee (Note9 and 10)	700,000	16,000	-	-	19,000	-	-	-	35,000	-	35,000
Issued for extension fee (Note 10 and 15)	600,000	14,000	-	-	16,000	-	-	-	30,000	-	30,000
Issued for services (Note 10)	811,111	57,500	-	-	-	-	-	-	57,500	-	57,500
Issed for license and royalty fees (Note 10 and 18)	3,333,334	250,000	-	-	-	-	-	-	250,000	-	250,000
Issued for acquisition of non-controlling interest (Note 10 and 14)	66,667	5,000	(5,000)	-	-	-	-	-	-	-	-
Share based payments	-	-	-	282,000	-	-	-	-	282,000	-	282,000
Share issue costs	-	(228,975)	-	-	-	-	-	-	(228,975)	-	(228,975)
Exchange gain on translating foreign operation	-	-	-	-	-	(13,013)	-	-	(13,013)	-	(13,013)
Net loss and comprehensive loss for the period	-	-	-	-	-	-	-	(1,677,619)	(1,677,619)	(8,007)	(1,685,626)
Balance at July 31, 2015	119,369,381 \$	2,719,740 \$	(5,000) \$	314,000 \$	566,399 \$	(15,285)	- \$	(2,740,442) \$	839,412 \$	(9,073) \$	830,339
Shares issued on exercise of warrants (Note 10)	8,000	439	-	-	(39)	-	-	-	400	-	400
Shares to be issued	-	-	-	-	-	-	50,000	-	50,000	-	50,000
Issued for non-cash consideration:											
Issued for services (Note 10)	456,668	22,833	-	-	-	-	-	-	22,833	-	22,833
Issed for license and royalty fees (Note 10 and 18)	692,431	51,932	-	-	-	-	-	-	51,932	-	51,932
Issed for conversion of debentures (Note 10, 15 and 20)	3,000,000	306,976	-	-	-	-	-	-	306,976	-	306,976
Share based payments (Note 20)		-	-	19,000	-	-	-	-	19,000	-	19,000
Exchange gain on translating foreign operation	-	-	-	-	-	(54)	-	-	(54)	-	(54)
Net loss for the period	-	-	-	-	-	-	-	(361,555)	(361,555)	153	(361,402)
Balance at October 31, 2015 (restated)	123,526,480 \$	3,101,920 \$	(5,000) \$	333,000 \$	566,360 \$	(15,339) \$	50,000 \$	(3,101,997) \$	928,944 \$	(8.920) \$	920,024

Nutritional High International Inc. Unaudited Condensed Interim Consolidated Statement of Cash Flows

(Expressed in Canadian Dollars)

For the three months ended October 31	2015	2014
OPERATING ACTIVITIES	(unaudited)	(unaudited)
Net Loss	\$ (361,402)	\$ (382,727)
Item not affecting cash:		
Amortization (Note 20)	14,247	-
Interest accretion (Note 20)	14,272	-
Shares issued for services	22,833	-
Share based payments (Note 11 and 20)	19,000	4,000
Allowances for amounts receivable (Note 5 and 20)	45,000	-
Prepaids	91,327	-
Change in the fair value of derivative liability (Note 20)	93,190	-
Net change in non-cash working capital:		
HST receivables and other receivables	85,405	(8,931)
Amounts due from Palo Verde LLC (Note 5 and 20)	(121,241)	(1,082)
Accounts payable and accrued liabilities	149,796	130,008
Cash Flow From (Used) in Operating Activities	52,427	(258,732)
INVESTING ACTIVITIES		
Amounts due from Palo Verde LLC (Note 5)	(13,163)	-
Property deposit (Note 7)	(6,582)	(5,554)
Cash Flow Used in Investing Activities	(19,745)	(5,554)
FINANCING ACTIVITIES		
Issuance of share capital, net of share issue costs (Note 10)	400	168,113
Shares to be issued	50,000	-
Cash Flow From Financing Activities	50,400	168,113
Net increase (decrease) in cash	\$ 83,082	\$ (97,173)
Effects of exchange rate changes on cash	486	(3,410)
Cash at beginning of period	19,567	617,066
Cash at end of period	\$ 103,135	\$ 517,483

1. Nature of Operations and Going Concern

Nutritional High International Inc. ("Nutritional High" or "the Company" or "NHII"), formerly Sonoma Capital Inc. is the parent company of Nutritional High Ltd., Nutritional High (Colorado) Inc., NHC Edibles LLC, NH Medicinal Dispensaries Inc., NH Medicinal (Minnesota) Inc., Eglinton Medicinal Advisory Ltd., NH Medicinals (Maryland) Inc., Small's Mills Holdings Inc., and Nutritional Traditions Inc. The Company's objective is to take advantage of the changing regulation governing the marijuana industry in the United States and Canada. The address of the Company's registered office is 77 King Street West, Suite 2905, Toronto, Ontario M5K 1H1. The Company is listed on the Canadian Securities Exchange (CSE) under symbol "EAT". The Company is also listed on the OTCQB Marketplace under US symbol: SPLIF.

The Company was incorporated under the name "Sonoma Capital Inc." on July 19, 2004 under the Canada Business Corporations Act.

The condensed interim consolidated financial statements (amended) were approved by the Board of Directors on January 29, 2016.

The Company is in the process of developing brands, trademark applications, and packaging for a confectionery line. The Company is also developing a licensing/franchising system to work with licensed marijuana edibles manufacturers and in this regard, is negotiating with parties who are licensed or seeking a manufacturing license.

The Company has earned rental income but not yet realized any revenue from its operations and will not be able to do so until a license/franchise arrangement is negotiated with licensed parties. As such, there is uncertainty with respect to the Company's ability to continue as a going concern, dependent upon such events as financing, entering into agreements with licensed parties, commencement of sales and market demand conditions. There is no assurance that any prospective project in the medical marijuana industry will be successfully initiated or completed. As is common with development stage companies, the Company is dependent upon obtaining necessary financing from time to time to finance its on-going and planned activities and to cover administrative costs.

At October 31, 2015 the Company had working capital (deficiency) of \$(74,589) (July 31, 2015 - \$116,439), had not yet achieved profitable operations, has accumulated losses of \$3,101,977 (July 31, 2015 - \$2,740,442) and expects to incur further losses in the development of its business, all of which describes the material uncertainties that cast significant doubt upon the Company's ability to continue as a going concern. The Company will require additional financing in order to conduct its planned business operations, meet its ongoing levels of corporate overhead and discharge its liabilities and commitments (Note 17) as they come due. There is no assurance that the Company will successfully raise this financing.

2. Basis of Presentation

2.1 Statement of compliance

The Company's condensed interim consolidated financial statements are prepared in accordance with International Financial Reporting Standards ("IFRS") and their interpretations as issued by the International Accounting Standards Board ("IASB"). The condensed consolidated interim financial statements have been prepared in conformity with IAS 34 *Interim Financial Reporting* and do not include all the information required for full annual consolidated financial statements in accordance with IFRS and should be read in conjunction with the audited consolidated financials for the year ended July 31, 2015.

2. Basis of Presentation (continued)

2.2 Basis of presentation

The unaudited condensed interim consolidated financial statements have been prepared on the historical cost basis except for certain financial instruments, which are measured at fair value, as explained in the accounting policies set out in Note 3.

2.3 Basis of consolidation

The unaudited condensed interim consolidated financial statements include the accounts of Nutritional High International Inc. and its wholly-owned subsidiaries Nutritional High Ltd., Nutritional High (Colorado), Inc., NHC Edibles, LLC, NH Medicinal (Minnesota) Inc., NH Medicinals (Maryland) Inc., Small's Mills Holdings Inc., and Nutritional Traditions Inc. with jurisdiction in US, and 51% owned subsidiary Eglinton Medicinal Advisory Ltd.

The subsidiaries are entities controlled by the Company. Control exists when the Company has power over an investee, when the Company is exposed, or has rights, to variable returns from the investee and when the Company has the ability to affect those returns through its power over the investee. The financial statements of subsidiaries are included in the consolidated financial statements from the date that control commences until the date control ceases.

Non-controlling interest is shown as a component of equity on the statement of financial position and the share of the loss attributable to non-controlling interest is shown as a component of loss for the year in the statement of loss and comprehensive loss.

The functional currency of the Company, Nutritional High Ltd. and Eglinton Medical Advisory Ltd. is the Canadian dollar, which is the presentation currency of the unaudited condensed interim consolidated financial statements. The functional currency of US subsidiaries (Nutritional High (Colorado), Inc, NHC Edibles, LLC, NH Medicinal (Minnesota), Inc., NH Medicinals (Maryland) Inc., Small's Mills Holdings Inc., and Nutritional Traditions Inc.) is the US dollar.

Intercompany balances and transactions, and unrealized gains arising from intercompany transactions are eliminated in preparing the unaudited condensed interim consolidated financial statements.

2.4 New and revised standards and interpretations to be adopted in the future

At the date of authorization of these unaudited condensed interim consolidated financial statements, the IASB and IFRIC has issued the following new and revised Standards and Interpretations which are not yet effective for the relevant reporting periods and which the Company has not early adopted. However, the Company is currently assessing what impact the application of these standards or amendments will have on the consolidated financial statements of the Company.

- Pronouncements effective for annual periods beginning on or after January 1, 2016
 - IAS 1 Presentation of Financial Statements Amendments are designed to further encourage companies to apply professional judgment in determining what information to disclose in their financial statements.

IAS 16 Property, Plant and Equipment and IAS 38 Intangible Assets Amendments clarify that the use of revenue-based methods to calculate the depreciation of an asset are not appropriate because revenue generated by an activity that includes the use of an asset generally reflects factors other than the consumption of the economic benefits embodied in the asset.

2. Basis of Presentation (continued)

2.4 New and revised standards and interpretations to be adopted in the future (continued)

Pronouncements effective for annual periods beginning on or after January 1, 2018

In July 2014, the IASB issued the final version of IFRS 9, Financial Instruments. The new standard will replace IAS 39, Financial instruments: recognition and measurement. The final amendments made in the new version include guidance for the classification and measurement of financial assets and a third measurement category for financial assets, fair value through other comprehensive income. The standard also contains a new expected loss impairment model for debt instruments measured at amortized cost or fair value through other comprehensive income, lease receivables, contract assets and certain written loan commitments and financial guarantee contracts. The standard is effective for annual periods beginning on or after January 1, 2018 and must be applied retrospectively with some exceptions. Early adoption is permitted. Restatement of prior periods in relation to the classification and measurement, including impairment, is not required. The Company has not yet assessed the impact of this new standard.

3. Summary of Significant Accounting Policies

3.1 Share based payments

Share based payment transactions

Employees (including directors and senior executives) of the Company receive a portion of their remuneration in the form of share based payment transactions, whereby they render services as consideration for equity instruments ("equity settled transactions").

In situations where equity instruments are issued to non-employees and some or all of the goods or services received by the entity as consideration cannot be specifically measured, they are measured at fair value of the share based payment. The fair value of the share based payments is recognized together with a corresponding increase in equity over a period that services are provided or goods are received.

Equity settled transactions

The costs of equity settled transactions with employees are measured by reference to the fair value of the equity instrument at the date on which they are granted.

The costs of equity settled transactions are recognized, together with a corresponding increase in equity, over the period in which the performance and/or service conditions are fulfilled, ending on the date on which the relevant employees become fully entitled to the award ("the vesting date"). The cumulative cost is recognized for equity settled transactions at each reporting date until the vesting date reflects the Company's best estimate of the number of equity instruments that will ultimately vest. The profit or loss charge or credit for a period represents the movement in cumulative expense recognized as at the beginning and end of that period and the corresponding amount is represented in share based payment reserve.

No expense is recognized for awards that do not ultimately vest.

Where the terms of an equity settled award are modified, the minimum expense recognized is the expense as if the terms had not been modified. An additional expense is recognized for any modification which increases the total fair value of the share based payment arrangement, or is otherwise beneficial to the employee as measured at the date of modification. The dilutive effect of outstanding options is reflected as additional dilution in the computation of loss per share.

3. Summary of Significant Accounting Policies (continued)

3.2 Loss per share

Basic loss per share is calculated using the weighted number of shares outstanding. Diluted loss per share is calculated using the weighted average number of common and potential common shares outstanding during the period. In order to determine diluted loss per share, it is assumed that any proceeds from the exercise of dilutive stock options and warrants would be used to repurchase common shares at the average market price during the period, with the incremental number of shares being included in the denominator of the diluted loss per share calculation. The diluted loss per share calculation excludes any potential conversion of options and warrants that would increase earnings per share or decrease loss per share. Total shares issuable from warrants were excluded from the computation of diluted loss per share because they were anti-dilutive for the period ended October 31, 2015.

3.3 Taxation

Current income tax

Current income tax assets and liabilities for the current and prior periods are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted by the date of the statement of financial position.

Deferred income tax

Deferred income tax is provided using the liability method on temporary differences at the date of the statement of financial position between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes.

Deferred income tax liabilities are recognized for all taxable temporary differences, except:

- where the deferred income tax liability arises from the initial recognition of goodwill or of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; and
- in respect of taxable temporary differences associated with investments in subsidiaries, associates and interests in joint ventures, where the timing of the reversal of the temporary differences can be controlled and it is probable that the temporary differences will not reverse in the foreseeable future.

Deferred income tax assets are recognized for all deductible temporary differences, carry forward of unused tax credits and unused tax losses, to the extent that it is probable that taxable profit will be available against which the deductible temporary differences and the carry forward of unused tax credits and unused tax losses can be utilized except:

 where the deferred income tax asset relating to the deductible temporary difference arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; and

3. Summary of Significant Accounting Policies (continued)

3.3 Taxation (continued)

Deferred income tax (continued)

• in respect of deductible temporary differences associated with investments in subsidiaries, associates and interests in joint ventures, deferred income tax assets are recognized only to the extent that it is probable that the temporary differences will reverse in the foreseeable future and taxable profit will be available against which the temporary differences can be utilized.

The carrying amount of deferred income tax assets is reviewed at each date of the statement of financial position and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred income tax asset to be utilized. Unrecognized deferred income tax assets are reassessed at each date of the statement of financial position and are recognized to the extent that it has become probable that future taxable profit will allow the deferred tax asset to be recovered.

Deferred income tax assets and liabilities are measured at the tax rates that are expected to apply to the year when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the date of the statement of financial position.

Deferred income tax relating to items recognized directly in equity is recognized in equity and not in the statement of comprehensive loss.

3.4 Financial assets

All financial assets are initially recorded at fair value and designated upon inception into one of the following four categories: held to maturity, available for sale, loans and receivables or at fair value through profit or loss ("FVTPL").

Financial assets classified as FVTPL are measured at fair value with unrealized gains and losses recognized through earnings. The Company's cash is classified as FVTPL.

Financial assets classified as loans and receivables and held to maturity are measured at amortized cost using the effective interest rate method. The Company's amounts due from Palo Verde LLC and other receivables except for HST receivable are classified as loans and receivables.

Financial assets classified as available for sale are measured at fair value with unrealized gains and losses recognized in other comprehensive loss except for losses in value that are considered other than temporary. At October 31, 2015, the Company has not classified any financial assets as available for sale.

Transactions costs associated with FVTPL financial assets are expensed as incurred, while transaction costs associated with all other financial assets are included in the initial carrying amount of the asset.

3. Summary of Significant Accounting Policies (continued)

3.5 Financial liabilities

All financial liabilities are initially recorded at fair value and designated upon inception as FVTPL or other financial liabilities.

Financial liabilities classified as other financial liabilities are initially recognized at fair value less directly attributable transaction costs. After initial recognition, other financial liabilities are subsequently measured at amortized cost using the effective interest method. The effective interest method is a method of calculating the amortized cost of a financial liability and of allocating interest expense over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash payments through the expected life of the financial liability, or, where appropriate, a shorter period. The Company's accounts payable and accrued liabilities, and convertible debentures are classified as other financial liabilities.

Financial liabilities classified at FVTPL include financial liabilities held for trading and financial liabilities designated upon initial recognition at FVTPL. Derivatives, including separated embedded derivatives are classified as held for trading unless they are designated as effective hedging instruments. Fair value changes on financial liabilities classified at FVTPL are recognized through the statement of comprehensive loss. At October 31, 2015, the Company has classified the conversion feature of the convertible debentures as financial liabilities at FVTPL.

3.6 Impairment of financial assets

The Company assesses at each date of the statement of financial position whether a financial asset is impaired. Management has concluded that additional impairment for amounts due from Palo Verde LLC are recognized as at October 31, 2015 (Note 5).

Assets carried at amortized cost

If there is objective evidence that an impairment loss on assets carried at amortized cost has been incurred, the amount of the loss is measured as the difference between the asset's carrying amount and the present value of estimated future cash flows discounted at the financial asset's original effective interest rate. The carrying amount of the asset is then reduced by the amount of the impairment. The amount of the loss is recognized in profit or loss.

If, in a subsequent period, the amount of the impairment loss decreases and the decrease can be related objectively to an event occurring after the impairment was recognized, the previously recognized impairment loss is reversed to the extent that the carrying value of the asset does not exceed what the amortized cost would have been had the impairment not been recognized. Any subsequent reversal of an impairment loss is recognized in profit or loss.

Available-for-sale

If an available for sale asset is impaired, an amount comprising the difference between its cost and its current fair value, less any impairment loss previously recognized in profit or loss, is transferred from equity to profit or loss. Reversals in respect of equity instruments classified as available for sale are not recognized in profit or loss.

3. Summary of Significant Accounting Policies (continued)

3.7 Provisions

Provisions are recognized when the Company has a present obligation (legal or constructive) that has arisen as a result of a past event and it is probable that a future outflow of resources will be required to settle the obligation, provided that a reliable estimate can be made of the amount of the obligation.

Provisions are measured at the present value of the expenditures expected to be required to settle the obligation using a pre-tax rate that reflects current market assessments of the time value of money and the risk specific to the obligation. The increase in the provision due to passage of time is recognized as interest expense.

3.8 Related party transactions

Parties are considered to be related if one party has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Parties are also considered to be related if they are subject to common control or common significant influence, related parties may be individuals or corporate entities. A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties.

3.9 Leases

Leases are classified as finance leases whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessee. All other leases are classified as operating leases.

The Company as lessor

Rental income from operating leases is recognized on a straight-line basis over the term of the relevant lease. Initial direct costs incurred in negotiating and arranging an operating lease are added to the carrying amount of the leased asset and recognized on a straight-line basis over the lease term.

3.10 Intangibles

Intangibles arise on the purchase of a license, which is accounted for using the cost model whereby capitalized costs are amortized on a straight-line basis over their estimated useful lives, as these assets are considered finite. Useful lives are reviewed annually and intangibles are subject to impairment testing.

3.11 Investment property

Investment property earns rental income and is not for sale in the ordinary course of business, is not used in the production or supply of goods or services or for administrative purposes. Investment property is carried at historical cost less any accumulated depreciation and impairment losses. Amortization is computed using the declining balance methods based on the estimated useful life of the assets. Useful life is reviewed at the end of each reporting period. Amortization is provided at rates as follows:

Building

4% Declining balance

3. Summary of Significant Accounting Policies (continued)

3.12 Impairment of non-financial assets

At each date of the statement of financial position, the Company reviews the carrying amounts of its tangible and intangible assets to determine whether there is an indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the Company estimates the recoverable amount of the cash generating unit to which the assets belong.

Recoverable amount is the higher of fair value less costs of disposal and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset.

If the recoverable amount of an asset (or cash generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash generating unit) is reduced to its recoverable amount. An impairment loss is recognized immediately in the statement of comprehensive loss.

For assets excluding goodwill, an assessment is made at each reporting date as to whether there is any indication that previously recognised impairment losses may no longer exist or may have decreased. If such indication exists, the Company estimates the asset's or cash-generating unit's recoverable amount. A previously recognised impairment loss is reversed only if there has been a change in the assumptions used to determine the asset's recoverable amount since the last impairment loss was recognised. The reversal is limited so that the carrying amount of the asset does not exceed its recoverable amount, nor exceed the carrying amount that would have been determined, net of depreciation, had no impairment loss been recognised for the asset in prior years. Such reversal is recognised in profit or loss and the carrying amount of the asset (cash-generating unit) is increased to the revised estimate of its recoverable amount.

3.13 Share issuance costs

Costs incurred in connection with the issuance of share capital are netted against the proceeds received net of tax. Costs related to the issuance of share capital and incurred prior to issuance are recorded as deferred share issuance costs and subsequently netted against proceeds when they are received.

3.14 Share capital

In situations where the Company issues units, the value of warrants is bifurcated and is included as the separate reserve of the Company's equity.

3.15 Convertible debentures

The proceeds received on issue of the Company's convertible debentures have been recorded as a liability on the consolidated statement of financial position. The convertible debentures contain an embedded derivative. The Company has designated the derivative as a financial liability at fair value through profit or loss. The Company revalues the convertible debenture derivative liability using recent arm's length market transactions and option pricing models at each reporting period.

3. Summary of Significant Accounting Policies (continued)

3.16 Significant accounting judgments and estimates

The preparation of these unaudited condensed interim consolidated financial statements requires management to make judgments and estimates and form assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. On an ongoing basis, management evaluates its judgments and estimates in relation to assets, liabilities, revenue and expenses. Management uses historical experience and various other factors it believes to be reasonable under the given circumstances as the basis for its judgments and estimates. Actual outcomes may differ from these estimates under different assumptions and conditions. The most significant estimates relate to recoverability of loan receivable and rent receivable (Note 5), valuation of deferred income tax amounts, and valuation of warrants and shares issued during private placements and measurement of derivative liability.

The most significant judgments relate to recognition of deferred tax assets and liabilities, assessment of functional currency and determination of derivative liability of convertible debt.

3.17 Foreign currency translation

Monetary assets and liabilities denominated in currencies other than Canadian dollars are translated into Canadian dollars at the rate of exchange in effect at the statement of financial position date. Non-monetary assets and liabilities are translated at the historical rates. Revenues and expenses are translated at the transaction exchange rate. Foreign currency gains and losses resulting from translation are reflected in net comprehensive loss for the period.

The assets and liabilities of entities with a functional currency that differs from the presentation currency are translated to the presentation currency as follows:

- Assets and liabilities are translated at the closing rate at the financial period end;
- Income and expenses are translated at average exchange rates (unless the average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case, income and expenses are translated at the rate on the dates of the transactions);
- Equity transactions are translated using the exchange rate at the date of the transaction; and
- All resulting exchange differences are recognized as a separate component of equity as reserve for foreign exchange.

When a foreign operation is disposed of, the relevant amount in the reserve for foreign exchange in other comprehensive income is transferred to profit or loss as part of the profit or loss on disposal.

On the partial disposal of a subsidiary that includes a foreign operation, the relevant proportion of such cumulative amount is reattributed to non-controlling interest. In any other partial disposal of a foreign operation, the relevant proportion is reclassified to profit or loss.

Foreign exchange gains or losses arising from a monetary item receivable from or payable to a foreign operation, the settlement of which is neither planned nor likely to occur in the foreseeable future, and which in substance, is considered to form part of the net investment in the foreign operation, are recognized in the reserve for foreign exchange.

4. HST receivable

HST consists of harmonized sales tax ("HST") due from the Canadian government.

5. Amounts due from Palo Verde LLC

The Company has lent Palo Verde LLC ("Palo") monies pursuant to a credit agreement and has leased property to Palo pursuant to two lease agreements, as disclosed below. The Company intends on entering into a branding arrangement with Palo in respect of its licensing arrangement (note 17).

	tober 31, 2015 estated)	July 31, 2015
Rental income receivable ⁽ⁱ⁾	\$ 294,187 \$	183,000
Loan receivable ⁽ⁱⁱ⁾	118,460	105,424
Interest receivable	19,472	9,418
	432,119	297,842
Impairment on amounts receivable(iii)	(145,000)	(100,000)
	\$ 287,119 \$	197,842

- (i) Rental income receivable is on the investment property in Colorado. Rent is deferred for the first 6, 9 and 9 months of the three respective leases, two leases commencing January 1, 2015 and the third on September 1, 2015 and accrues interest at 12% per annum to be paid no later than June 30, 2017 and September 30, 2017.
- (ii) Revolving line of credit of USD \$150,000 to Palo Verde LLC, of which \$118,460 (USD \$90,600) (July 31, 2015 USD \$80,600) and accrued interest of \$10,695 (USD \$8,180) (July 31, 2015 USD \$5,717) was receivable as at October 31, 2015. Advances through a promissory note are unsecured; bear interest at 12% per annum which are due on September 30, 2016. Accrued interest is payable in three monthly installments on September 30, 2016, October 31, 2016 and November 30, 2016. Palo Verde may extend the maturity date for up to an additional four successive one-year terms for a total of five years, but no later than July 22, 2020 for a fee equal to 1% of the outstanding revolving credit loan.
- (iii) An allowance was recorded in July 31, 2015 on account of the uncertainties surrounding recoverability of the loan and rents receivable in respect of timing and unexpected financing delays. An additional allowance of \$45,000 was recorded in October 31, 2015 as a result of balance outstanding from Palo Verde LLC.

6. Investment property

	Land	Building	Total	
Cost				
Balance at July 31, 2014	\$ -	\$ -	\$ -	
Additions	141,200	858,496	999,696	
Effect of movement in exchange rates	22,300	135,584	157,884	
Balance at July 31, 2015	163,500	994,080	1,157,580	
Effect of movement in exchange rates	(62)	(380)	(442)	
Balance at October 31, 2015	163,438	993,700	1,157,138	
Accumulated Amortization				
Balance at July 31, 2014	-	-	-	
Amortization for the year	-	25,523	25,523	
Effect of movement in exchange rates	-	2,475	2,475	
Balance at July 31, 2015	-	27,998	27,998	
Amortization for the period	-	10,084	10,084	
Effect of movement in exchange rates	-	(76)	(76)	
Balance at October 31, 2015	-	38,006	38,006	
Carrying Amounts				
Balance at July 31, 2014	_	-	-	
Balance at July 31, 2015	163,500	966,082	1,129,582	
Balance at October 31, 2015	\$ 163,438	\$ 955,694	\$ 1,119,132	

The fair value of the investment property as at October 31, 2015 and July 31, 2015 approximates the carrying value as the investment property was acquired during the year ended July 31, 2015 and management used the independent real estate appraiser to establish the acquisition price of the investment property.

7. Property Deposits

The Company through its owned subsidiary NH Medicinal Dispensaries Inc. made a refundable deposit of \$6,668 (USD \$5,100) on the purchase of the commercial property located in Illinois, USA, with a remaining commitment of USD \$345,000 upon closing (Note 19).

The Company through its subsidiary NH Medicinals (Maryland) Inc. made a refundable deposit of \$6,538 (USD \$5,000) on the purchase of the commercial property located in Maryland, USA. The acquisition price for the property is USD \$350,000. The settlement date is to be within 45 days after the Company receives Stage 1 license approval, but in no event, later than 365 days after the execution date of this contract.

8. Accounts Payable and Accrued Liabilities

Accounts payable and accrued liabilities of the Company are principally comprised of amounts outstanding for trade purchases relating to regular business activities and amounts payable for financing activities. The usual credit period taken for purchases is between 30 to 90 days.

8. Accounts Payable and Accrued Liabilities (continued)

The following is an aged analysis of accounts payable and accrued liabilities:

	October 31, 2015	July 31, 2015
	\$	\$
Less than 1 month	89,537	97,370
Over 1 month	280,601	174,904
Total accounts payable and accrued liabilities	\$ 370,138	\$ 272,274

9. Related Parties and Key Management

Key management includes the Company's directors, officers and any employees with authority and responsibility for planning, directing and controlling the activities of an entity, directly or indirectly.

For the three month period ended October 31, 2015, the Company incurred professional fees of \$18,000 (2014 - \$11,000) from Branson Corporate Services, a company in which a company with a related director has a 49% interest.

For the three month period ended October 31, 2015, the Company incurred consulting fees of \$48,000 (2014 - \$24,000) from FMI Capital Advisory Inc. (formerly Foundation Opportunities Inc.), a company with a related director.

For the three month period ended October 31, 2015, the Company incurred professional fees of \$9,646 (2014 - \$132,944) from Fogler Rubinoff, LLP, a law firm in which a director of the company is a partner.

Total key management compensation paid to the Chief Executive Officer, the Chief Operating Officer, and the VP Product Development amounted to \$64,510 (2014 - \$55,584) for the three month period ended October 31, 2015.

These expenses have been measured at their exchange amount, being the amounts negotiated and agreed to by the parties to the transactions. As at October 31, 2015, \$217,344 (July 31, 2015 - \$85,463) is included in accounts payable and accrued liabilities.

10. Share Capital

The Company is authorized to issue an unlimited number of common shares without par value.

On October 8, 2014, the Company closed a subscription for 4,000,000 units at \$0.025 per unit for gross proceeds of \$100,000. Each unit consisted of one common share and one half of one share purchase warrant, with each warrant exercisable into one common share at a price of \$0.05 per share until the earlier of 36 months from the date of issuance or 18 months following the date of a business combination between the Company and a public company pursuant to a reverse take-over, merger, amalgamation, take-over bid, insider bid, reorganization, joint venture, sale or exchange of assets or similar transaction or IPO. In connection with the subscription, the Company paid a finder's fee of \$8,000 and issued an aggregate of 320,000 finder's warrants (Note 9), exercisable into one common share at a price of \$0.025 per share until 18 months from the closing date.

On October 31, 2014, 3,566,638 warrants were exercised at \$0.05 per warrant for gross proceeds of \$178,332. An additional \$17,467 credited to share capital represents a transfer of the reserve for warrants in respect of the exercised warrants. The share purchase warrants have been amended to

10. Share Capital (continued)

include an early exercise provision of an additional warrant exercisable into one common share at a price of \$0.10 per share until 24 months from the date of issuance. As a result of the amendment, an additional 3,566,638 warrants were issued, as described in Note 12. The terms of any unexercised Company warrants outstanding at October 31, 2014 remain unchanged.

On March 13, 2015, 32,900,000 units at \$0.05 per unit were issued for gross proceeds of \$1,645,000 pursuant to the IPO. Each unit consisted of one common share and one half of one share purchase warrant, with each warrant exercisable into one common share at a price of \$0.07 per share until 24 months from the date of issuance.

On March 13, 2015, the Company issued 2,404,800 compensation options under a warrant indenture valued at \$63,000 based on the services provided. Each option is exercisable at \$0.05 per unit, and comprised of one common share and one half of one share purchase warrant, exercisable into one additional common share at a price of \$0.07 per share until 24 months from the date of issuance.

On March 18, 2015, the Company paid an extension fee of \$30,000 by issuing an aggregate of 600,000 units and one half of one share purchase warrant, exercisable into one common share at a price of \$0.07 per share until 24 months from the date of issuance (Note 14).

On March 18, 2015, the Company paid a going public success fee of \$35,000 by issuing an aggregate of 700,000 units and one half of one share purchase warrant, exercisable into one common share at a price of \$0.07 per share until 24 months from the date of issuance to FMI Capital Advisory (formerly Foundation Opportunities Inc.), a company with a related director.

On March 26, 2015, 400,000 warrants were exercised for gross proceeds of \$28,000. An additional \$8,827 credited to share capital represents a transfer of the reserve for warrants in respect of the exercised warrants.

On March 27, 2015, 400,000 warrants were exercised for gross proceeds of \$28,000. An additional \$8,827 credited to share capital represents a transfer of the reserve for warrants in respect of the exercised warrants.

On March 30, 2015, 12,000 compensation options under the warrant indenture were exercised for \$600 for 12,000 common shares and 6,000 share purchase warrants, exercisable at a price of \$0.07 per share until March 16, 2017. An additional \$314 credited to share capital represents a transfer of the reserve for warrants in respect of the exercised warrants.

On April 7, 2015, 160,000 warrants were exercised for \$4,000 for 160,000 common shares and 80,000 share purchase warrants, exercisable at a price of \$0.05 per share until April 8, 2016. An additional \$2,000 credited to share capital represents a transfer of the reserve for warrants in respect of the exercised warrants.

On April 8, 2015, 6,000 warrants were exercised for gross proceeds of \$420. An additional \$132 credited to share capital represents a transfer of the reserve for warrants in respect of the exercised warrants.

On April 20, 2015, 500,000 warrants were exercised for gross proceeds of \$35,000. An additional \$11,034 credited to share capital represents a transfer of the reserve for warrants in respect of the exercised warrants.

On June 5, 2015, the Company issued 3,333,334 shares valued at \$250,000 to satisfy the initial licensing and royalty commitment as described in Note 17.

On June 6, 2015, the Company issued 66,667 shares valued at \$5,000 in exchange for 2% interest in

Nutritional High International Inc.

Notes to the unaudited condensed interim consolidated Financial Statements For the three month period ended October 31, 2015 (expressed in Canadian Dollars)

10. Share Capital (continued)

NH Medicinal Dispensaries Inc. as described in Note 13.

On June 7, 2015, the Company issued 700,000 shares valued at \$52,500 as compensation for services where the fair value of shares was determined based on the value of services received.

On July 31, 2015, the Company issued 111,111 shares valued at \$5,000 as compensation for services where the fair value of shares was determined based on the value of services received.

Cash costs in connection with the transactions amounted to \$239,194.

On August 20, 2015, the Company issued 692,431 shares valued at \$51,932 as the final instalment on its initial licensing obligations, as described in Note 17.

On September 7, 2015, the Company issued 406,668 shares valued at \$20,333 as compensation for services where the fair value of shares was determined based on the value of services received.

On October 5, 2015, 8,000 warrants were exercised for gross proceeds of \$400. An additional \$39 credited to share capital represents a transfer of the reserve for warrants in respect of the exercised warrants.

On October 23, 2015, a holder of the convertible debentures (Note 14) converted \$180,000 in convertible debentures into 3,000,000 common shares of the Company at a share price of \$0.06 per share.

On October 26, 2015, the Company issued 50,000 shares valued at \$2,500 as compensation for services where the fair value of shares was determined based on the value of services received.

11. Reserve for Share Based Payments

The Company established a stock option plan to provide additional incentive to its officers, directors, employees and consultants in their effort on behalf of the Company in the conduct of its affairs. Options vest immediately, unless otherwise stated, and expire on the fifth anniversary from the date of issue unless otherwise specified. The maximum number of common shares reserved for issuance for options that may be granted under the Plan is 10% of the total issued and outstanding Common shares, which was 12,352,648 at October 31, 2015.

The following table reflects the continuity of options for the period ended October 31, 2015:

	Number of Options	Amount
Balance - July 31, 2014	2,800,000	\$ 28,000
Granted	8,400,000	286,000
Expired	(200,000)	-
Balance – July 31, 2015	11,000,000	314,000
Granted	1,100,000	19,000
Expired	(1,300,000)	-
Balance – October 31, 2015	10,800,000	\$ 333,000

11. Reserve for Share Based Payments (continued)

During the period ended October 31, 2015, the Company granted 1,100,000 stock options to an officer to purchase common shares of the Company at the exercise price of \$0.075 exercisable until 60 months from the date of issuance, for a stock option expense of \$4,000. These stock options are vesting quarterly in equal amounts over 3 years. A stock option expense of \$15,000 was recorded in relation to the vesting of the options issued through July 31, 2015.

During the year ended July 31, 2015, the Company granted 8,400,000 stock options to certain officers, directors, consultants and advisory board members to purchase common shares of the Company at the exercise price of \$0.10 exercisable until 60 months from the date of issuance.

Vesting periods on the options granted during the year ended July 31, 2015 are as follows: 7,050,000 stock options vested immediately upon issuance, 300,000 stock options issued on March 18, 2015, 50% of which vested immediately and the remaining 50% vest monthly over 6 months, 2,000,000 stock options issued on March 18, 2015, which vest in stages over a minimum of 12 months with no more than ¼ of options vesting any three month period, and the remaining vest quarterly over next 24 months.

The estimated fair value of share based compensation during the period ended October 31, 2015 was determined using the Black-Scholes option pricing model with the following assumptions:

	September 16, 2015
Number of options	1,100,000
Share price	\$0.030
Risk-free interest rate	0.81%
Expected life of options	5 years
Expected volatility	202%
Expected dividend yield	0%
Fair value	\$32,000

The estimated fair value of share based compensation during the year ended July 31, 2015 was determined using the Black-Scholes option pricing model with the following assumptions:

	October 10, 2014	March 18, 2015	April 1, 2015	April 6, 2015	June 10, 2015	July 22, 2015	Total
Number of options	400,000	6,950,000	250,000	150,000	400,000	250,000	
Share price	\$0.025	\$0.050	\$0.095	\$0.110	\$0.080	\$0.050	
Risk-free interest rate	1.56%	0.75%	0.98%	0.98%	0.95%	0.83%	
Expected life of options	5 years	5 years	5 years	5 years	5 years	5 years	
Expected life of options Expected volatility	5 years 100%	5 years 100%	5 years 209%	5 years 209%	5 years 209%	5 years 209%	
	- ,	- ,	. ,	. ,	- ,	. ,	

Option pricing models require the input of highly subjective assumptions including the expected price volatility. Changes in the subjective input assumptions can materially affect the fair value estimated, and therefore, the existing models do not necessarily provide a reliable measure of the fair value of the Company's stock options. Expected volatility is based on comparable companies.

The weighted average remaining contractual life for outstanding options is as follows:

Exercise Price	Number of Options	Weighted Average cise Price	Weighted Average Remaining Life (years)	Number of Options - exercisable
\$0.10	10,800,000	\$ 0.0975	4.30	8,700,000

12. Reserve for Warrants

The following table reflects the continuity of warrants for the period ended October 31, 2015:

	Number of Warrants	Amount
Balance – July 31, 2014	13,650,006	\$ 65,000
Warrants pursuant to private placement and option agreement (Note 10)	5,966,638	88,000
Warrants pursuant to IPO (Note 10)	16,450,000	363,000
Compensation warrants (Note 10)	2,410,800	64,000
Warrants issued for success and extension fees (Note 10)	650,000	35,000
Warrants exercised (Note 10)	(5,044,638)	(48,601)
Balance – July 31, 2015	34,082,806	566,399
Warrants exercised (Note 10)	(8,000)	(39)
Balance - October 31, 2015	34,074,806	\$ 566,360

During the year ended July 31, 2015, the Company issued warrants to purchase common shares, valued at \$550,000 using the Black-Scholes option pricing model using the following assumptions:

	October 8, 2014	October 31, 2014	March 13, 2015	March 18, 2015	March 30, 2015	April 7, 2015	Total
Number of warrants	2,320,000	3,566,638	18,854,800	650,000	6,000	80,000	
Share price	\$0.025	\$0.100	\$0.050	\$0.130	\$0.110	\$0.100	
Risk-free interest rate	1.05%	1.04%	0.49%	0.49%	0.49%	0.67%	
Expected life of warrants	1.5 years	2 years	2 years	2 years	2 years	2 years	
Expected volatility	100%	100%	100%	209%	209%	209%	
Expected dividend yield	0%	0%	0%	0%	0%	0%	
Valued at	\$18,000	\$64,000	\$426,000	\$35,000	\$1,000	\$6,000	\$550,000

Warrants to purchase common shares carry exercise prices and terms to maturity at October 31, 2015 as follows:

Date of Issue	No. of warrants	Exercise Price (\$)	Expiry Date
October 8, 2014	2,000,000	0.050	April 7, 2016
October 8, 2014	160,000	0.025	April 7, 2016
June 27, 2014	150,000	0.100	June 26, 2016
October 31, 2014	3,566,638	0.100	October 31, 2016
May 16, 2014	7,536,789	0.050	December 27, 2015
May 30, 2014	1,082,399	0.050	December 27, 2015
June 20, 2014	1,306,180	0.050	December 27, 2015
March 13, 2015	15,800,000	0.070	March 12, 2017
March 13, 2015	2,392,800	0.050	March 12, 2017
April 7, 2015	80,000	0.050	April 6, 2017
•	34,074,806		•

13. Non-controlling Interest

The Company's 51% interest in Eglinton Medicinal Advisory Ltd. is consolidated into the Company's consolidated financial statements. The 49% interest attributable to a minority shareholder is then presented as "non-controlling interest" within shareholders' equity on the consolidated statement of financial position. Net loss and comprehensive loss is allocated between the Company's 51% ownership and non-controlling 49% ownership interest. The Company recorded \$8,920 (July 31, 2015 - \$9,073) of the subsidiary's net loss and comprehensive loss related to the non-controlling interest during the period ended October 31, 2015.

14. Convertible Debentures

On November 17, 2014, the Company closed its non-brokered private placement of secured convertible debentures for total gross proceeds of \$600,000 as follows:

- a. Senior convertible debenture of \$450,000, bearing interest at 12%, maturing in 24 months from date of issue, and secured by a first ranking general security interest over all assets of the Company. The senior convertible debenture is convertible into common shares of the Company at any time prior to the maturity date at a price equal to a 20% premium to the price at which the Company completes its going public transaction or \$0.06 per Company share ("Conversion Price"). If the Company fails to complete the going public transaction on or before January 31, 2015, the Conversion Price will be reduced to \$0.05 per Company share. If the Company completes the going public transaction on or before January 31, 2015, but less than \$1,000,000 is raised, the Conversion Price will be equal to the price at which the Company completes the going public transaction ("Conversion Price Adjustment") and the Company will issue to the holder 450,000 Company shares immediately prior to closing the going public transition. On January 19, 2015, an amendment was made to the agreement to extend the going public date from January 31, 2015 to March 16, 2015, in consideration for \$30,000, convertible into units at the offering price. On October 23, 2015, \$180,000 of the debentures were converted into 3,000,000 common shares (Note 10). An additional \$170,000 of the debentures was converted subsequent to period end (Note 19).
- b. Subordinate convertible debenture of \$150,000, bearing interest at 12%, maturing in 24 months from date of issue, and secured by a general security interest over all assets of the Company, subordinate to the senior convertible debenture. The group of lenders is comprised of directors of the Company. The subordinate convertible debenture carries the same Conversion Prices and Conversion Price Adjustment as the senior convertible debenture described above. On January 19, 2015, an amendment was made to the agreement to extend the going public date from January 31, 2015 to March 16, 2015.

The debentures are classified as a liability at amortized cost for the host component and its embedded derivative was classified at fair value through profit and loss as the conversion feature of debentures failed equity classification. The fair value of the derivative was calculated using the Black-Scholes model with the following assumptions: (November 17, 2014 and July 31, 2015: share price: \$.02 and \$.045; risk free interest rate: 1%; expected life: 2 and 1.3 years; expected volatility 100% and 209%; dividend yield 0%). The assumptions used in the Black-Scholes model are based on management's estimate of the rates that are reflective for the Company. Changes in these estimates could result in significant changes in the fair value of the derivative. The discount is being accreted over the term of the debenture utilizing the effective interest rate method at a 5.22% discount rate.

A fair value adjustment loss on the convertible debentures for the period ended October 31, 2015, of \$93,190 (July 31, 2015: \$277,753) has been reflected in the consolidated statement of comprehensive loss as a change in the fair value of the derivative liability. The fair value of the derivative liability at the inception was \$52,312. The interest and accretion expense in the amount of \$18,148 and \$14,272 are recorded as a finance cost.

14. Convertible Debentures (continued)

The debt issue costs in the amount of \$30,000 were recorded against the debentures liability and amortized using the effective interest method. As at October 31, 2015, \$9,372 is recorded as accrued interest in accounts payable and accrued liabilities.

15. Management of Capital

The Company manages its capital structure and makes adjustments to it, based on the funds available to the Company, in order to support the development of its planned business activities. The Board of Directors does not establish quantitative return on capital criteria for management, but rather relies on the expertise of the Company's management to sustain future development of the business. In order to carry out the planned business activities and pay for administrative costs, the Company will spend its existing working capital and raise additional funds as needed. Management reviews its capital management approach on an ongoing basis and believes that this approach, given the relative size of the Company, is reasonable. There were no changes in the Company's approach to capital management during the period ended October 31, 2015. The Company is not subject to externally imposed capital requirements.

The Company considers its capital to be shareholders' equity, which is comprised of share capital, reserve for warrants, share based payments and deficit, which as at October 31, 2015 totaled \$949,283.

The Company's objective when managing capital is to obtain adequate levels of funding to support its business activities, to obtain corporate and administrative functions necessary to support organizational functioning and obtain sufficient funding to further the development of its business. The Company raises capital, as necessary, to meet its needs and take advantage of perceived opportunities and, therefore, does not have a numeric target for its capital structure. Funds are primarily secured through equity capital raised by way of private placements, initial public offering and issuance of convertible debentures. There can be no assurance that the Company will be able to continue raising equity capital in this manner.

16. Financial Instruments

Fair Value of Financial Instruments

The fair value hierarchy that reflects the significance of inputs used in making fair value measurements as follows:

- Level 1 quoted prices in active markets for identical assets or liabilities;
- Level 2 inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. from derived prices); and
- Level 3 inputs for the asset or liability that are not based upon observable market data.

Assets are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.

The Company designated its cash as fair value through profit and loss, which is measured at fair value and is classified as Level 1. The Company designated its derivative liability from convertible debentures as fair value through profit and loss which is measured at fair value and classified as level 2.

The carrying value of the Company's other receivable, amounts due from Palo Verde LLC and accounts payable and accrued liabilities and convertible debentures (except for derivative liability

16. Financial Instruments

Fair Value of Financial Instruments (continued)

which is recorded at fair value) approximate their fair value due to the relatively short periods to maturity of these instruments.

Fair value estimates are made at a specific point in time, based on relevant market information and information about financial instruments. These estimates are subject to and involve uncertainties and matters of significant judgment, therefore cannot be determined with precision. Changes in assumptions could significantly affect the estimates.

A summary of the Company's risk exposures as it relates to financial instruments are reflected below:

Credit risk

Credit risk is the risk of loss associated with counterparty's inability to fulfill its payment obligations. The Company's credit risk is primarily attributable to cash and amounts due from Palo Verde LLC and rent receivable (Note 5). The Company has no significant concentration of credit risk arising from operations. Cash is held with a reputable Canadian chartered bank which is closely monitored by management. The Board of Directors meets on a quarterly basis to review and assess the risk profile of the loan. Management believes that the credit risk concentration with respect to financial instruments included in cash and other receivable is not material for the Company.

Liquidity risk

Liquidity risk is the risk that the Company will not have sufficient cash resources to meet its financial obligations as they come due. The Company's liquidity and operating results may be adversely affected if the Company's access to the capital market is hindered, whether as a result of a downturn in stock market conditions generally or related to matters specific to the Company. The Company generates cash flow primarily from its financing activities. The Company's approach to managing liquidity risk is to ensure that it will have sufficient liquidity to meet liabilities when due. As at October 31, 2015, the Company had current assets of \$295,549 (July 31, 2015 - \$388,713) and current liabilities of \$370,138 (July 31, 2015 - \$272,274). All of the Company's financial liabilities and receivables, excluding a loan receivable (Note 5), have contractual maturities of less than 90 days and are subject to normal trade terms. As at October 31, 2015, working capital (deficiency) of the Company is \$(74,589) (July 31, 2015 - \$116,439).

Foreign currency exchange risk

The Company conducts a portion of its purchases in US dollars which results in the foreign currency exchange risk. The Company does not consider its exposure to foreign currency exchange risk to be material.

An increase (decrease) of 10% in the currency exchange rate of the Canadian dollar versus US dollar would have impacted net loss by \$1792 (\$1,792) as a result of the Company's exposure to currency exchange rate fluctuations.

Interest rate risk

Interest rate risk is the potential for financial loss arising from changes in interest rates. Financial instruments that potentially subject the Company to interest rate risk include financial liabilities with fixed interest rates.

The Company manages interest rate risk by monitoring market conditions and the impact of interest rate fluctuations on its debt.

Nutritional High International Inc.

Notes to the unaudited condensed interim consolidated Financial Statements
For the three month period ended October 31, 2015
(expressed in Canadian Dollars)

16. Financial Instruments

Fair Value of Financial Instruments (continued)

Net earnings are sensitive to the impact of a change in interest rates on the average balance of interest bearing financial liabilities during the year.

An increase (decrease) of 25 basis points would have impacted net loss by \$2,467 (\$2,467) as a result of the Company's exposure to interest rate fluctuations.

17. Licensing and Royalty Agreement

On June 5, 2015, the Company entered into the agreement with Purple Haze Properties LLC for the exclusive right to manufacture and distribute marijuana and hemp oil-infused products, and non-exclusive rights to manufacture and distribute certain apparel and accessories in the United States and Canada.

Under the terms of the agreement, the Company is to issue 3,333,334 common shares (Note 10) valued at USD\$250,000 to pay for the annual exclusivity fee (USD \$200,000) for the first out of five years and royalties USD \$50,000 which was due on signing the agreement. The agreement provides for annual exclusivity fees and royalties of no less than USD \$1,000,000 over five years with an additional renewal option for an additional five years. The agreement term commences the earlier of the first product sale or October 1, 2015, with minimums payable in cash or shares at the Company's option.

18. Segment Information

The Company has one reportable segment which is Marijuana-Infused Products. The segment reflects the basis on which management measures performance and makes decisions regarding the allocation of resources.

19. Subsequent events

On November 5, 2015, a holder of the convertible debentures (Note 14) converted \$100,000 in convertible debentures into 1,666,667 common shares of the Company at a share price of \$0.06 per share.

On November 5, 2015, 1,600,000 warrants were exercised for gross proceeds of \$80,000.

On November 11, 2015, a holder of the convertible debentures (Note 14) converted \$70,000 in convertible debentures into 1,166,667 common shares of the Company at a share price of \$0.06 per share.

During the year ended July 31, 2015, the Company through its owned subsidiary NH Medicinal Dispensaries Inc. made a refundable deposit of \$6,668 (USD \$5,000) on the purchase of the commercial property located in Lawrenceville, Illinois, USA. On November 4, 2015, the vendor of the real estate property in Illinois where the Company's dispensary will be located agreed to provide a buyer take-back mortgage in the amount of USD \$250,000. The mortgage will have a 15 year amortization period, bearing an interest at the rate of 6% and be due in two years from the date of issuance as a balloon payment. The acquisition price for the commercial property was USD \$350,000 and the Company closed the acquisition on November 25, 2015.

On November 17, 2015, 1,000,000 warrants were exercised for gross proceeds of \$50,000.

On December 2, 2015, the Company completed a non-brokered private placement of 4,200,000 units at \$0.05 per unit for gross proceeds of \$210,000. Each unit consisted of one common share and one

19. Subsequent events (continued)

half of one share purchase warrant, with each warrant exercisable into one common share at a price of \$0.07 per share for a period of 18 months from the date of issuance.

On December 21, 2015, the company has amended the exercise period of its share purchase warrants issued on June 27, 2014 from eighteen months to twenty one months. 5,563,348 Series I Warrants with expiry date of December 27, 2015 will now expire on expire on March 27, 2016. The Warrants exercise price of \$0.05 per Common Share remains unchanged.

On December 21, 2015, the Company's board has approved for the issuance 500,000 stock options. Each Stock Option is exercisable into Common Shares at a price of \$0.075 per Common Share.

On December 21, 2015, the Company has entered into an amending agreement with the holder of Senior Convertible Debenture ("Holder") to provide for the prepayment. The Company has agreed to issue 3,750,000 Common Share purchase warrants ("Warrants") to the holder of the Secured Convertible Debenture immediately, and pay a fee in the amount of \$27,000 if the Company elects to proceed with pre-payment. Each Warrant entitles the Holder to purchase one Common Share at an exercise price of \$0.06 per Common Share for a period of two years from the date of the Warrant. As of the date hereof, the principal amount of the Senior Convertible Debenture outstanding is \$100,000.

On January 6, 2016, the Company entered into an equity purchase agreement ("EPA") with Kodiak Capital Group LLC ("Kodiak"), pursuant to which Kodiak has agreed to purchase up to USD \$1 million of Nutritional High's common shares.

20. Restatement

The October 31, 2015 interim consolidated financial statements was previously published on SEDAR, on December 18, 2015. In connection with an Form F-1 filing in the United States of American, the following changes were made to more accurately account for transactions which took place during the quarter.

Unaudited Condensed Interim Consolidated Statements of Financial Position			
	As reported	Adjustment	Restated
Amounts due from Palo Verde LLC	326,283	(39,164)	287,119
Prepaid license	249,780	(4,163)	245,617
Convertible debentures	372,213	1,969	374,182
Derivative liability	291,894	4,385	296,279
Share Capital	2,974,944	126,976	3,101,920
Reserve for share based payments		•	
Accumulated deficit	359,000	(26,000)	333,000
	(2,951,340)	(150,657)	(3,101,997)
Unaudited Condensed Interim Consolidated Statements of Loss and Comprehensive Loss	As reported	Adjustment	Restated
	As reported 45,000	Adjustment (26,000)	Restated 19,000
Statements of Loss and Comprehensive Loss	·		
Statements of Loss and Comprehensive Loss Share based payments	45,000	(26,000)	19,000
Statements of Loss and Comprehensive Loss Share based payments Change in fair value of derivative liability	45,000 (38,171)	(26,000) 131,361	19,000 93,190
Statements of Loss and Comprehensive Loss Share based payments Change in fair value of derivative liability Finance costs	45,000 (38,171) 30,451	(26,000) 131,361 1,969	19,000 93,190 32,420
Statements of Loss and Comprehensive Loss Share based payments Change in fair value of derivative liability Finance costs Amortization	45,000 (38,171) 30,451 10,084	(26,000) 131,361 1,969 4,163	19,000 93,190 32,420 14,247